Recent Press Releases

Takeda Announces Publication in The Lancet of a Post Hoc Analysis of Data from the EXAMINE Cardiovascular Safety Outcomes Trial

Osaka, Japan, March 10, 2015 – Takeda Pharmaceutical Company Limited (Takeda) announced that a post hoc analysis of data from the global EXAMINE (EXamination of CArdiovascular OutcoMes:...

Portola Pharmaceuticals Announces Proposed Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., March 9, 2015 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. (Nasdaq:PTLA) today announced that it has commenced an underwritten public offering of shares of its...

Actavis Launches Generic Version of Temovate® (clobetasol cream 0.05%)

DUBLIN, March 9, 2015 /PRNewswire/ -- Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, today announced that it has launched a generic version of Fougera's Temovate®...

U.S. Biosimilar Approvals Poised to Grow, but Market Uptake Faces Several Challenges

BOSTON – March 5, 2015 – Biosimilar approvals in the United States are expected to increase during the next five years, but safety concerns among physicians and the need for greater...

NICE draft guidance recommends apixaban (Eliquis) for treating and preventing potentially fatal blood clots

NICE draft guidance recommends apixaban (Eliquis) for treating and preventing potentially fatal blood clots In draft guidance published today healthcare guidance body NICE has recommended the...

FDA approves first biosimilar ZarxioTM (filgrastim-sndz) from Sandoz

Sandoz is the first company to receive approval of a biosimilar in the US through the new FDA biosimilars pathway established under BPCIA Zarxio is approved for all indications included in the...

FDA approves first biosimilar product Zarxio

The U.S. Food and Drug Administration today approved Zarxio (filgrastim-sndz), the first biosimilar product approved in the United States. Biological products are generally derived from a living...

Mallinckrodt Pharmaceuticals To Expand Hospital Growth Platform With Ikaria, Inc. Acquisition

Enters definitive agreement to acquire Ikaria, Inc. for $2.3 billion from a group of investors led by Madison Dearborn Partners Transaction expected to be accretive to Mallinckrodt's fiscal...

Actavis Confirms District Court Ruling In Atelvia® Patent Litigation

DUBLIN, March 4, 2015 /PRNewswire/ -- Actavis plc (NYSE: ACT) today confirmed that the United States District Court for the District of New Jersey has found that United States Patent Nos. 7,645,459...

Lilly and IU School of Medicine Partner on Rotation Program for Medical Students

INDIANAPOLIS, March 4, 2015 /PRNewswire/ -- Students from Indiana University School

AbbVie to Acquire Pharmacyclics, including its blockbuster product Imbruvica®, Creating an Industry Leading Hematological Oncology Franchise

- Adds Imbruvica® a first in class BTK inhibitor approved in multiple indications for blood cancers. - Extensive clinical program with over 50 studies ongoing evaluating Imbruvica® as a...

FDA expands approved use of Opdivo to treat lung cancer

The U.S. Food and Drug Administration today expanded the approved use of Opdivo (nivolumab) to treat patients with advanced (metastatic) squamous non-small cell lung cancer (NSCLC) with progression...

Genentech response to Novation survey

Genentech's goal is and always will be to get people the medicines they need. We continue to believe the specialty distribution model is the best way for us to ensure patients receive our infused...

Testosterone Products: Drug Safety Communication - FDA Cautions About Using Testosterone Products for Low Testosterone Due to Aging; Requires Labeling Change to Inform of Possible Increased Risk of Heart Attack And Stroke

Testosterone Products: Drug Safety Communication - FDA Cautions About Using Testosterone Products for Low Testosterone Due to Aging; Requires Labeling Change to Inform of Possible Increased Risk of...

Provides 2015 Adjusted Diluted EPS Guidance Range of $4.00 to $4.30, Representing Year-Over-Year Growth of 17%, or 21% on a Constant Currency Basis

Anticipates 2015 Revenues of $9.6 billion to $10.1 billion, Representing Year-Over-Year Growth of 28%, or 33% on a Constant Currency Basis POTTERS BAR, England and PITTSBURGH, March 2, 2015...

Survey Results: Genentech's Decision to Change Distribution of Critical Cancer Drugs Raises Costs, Reduces Availability

IRVING, Texas--(BUSINESS WIRE)--A national survey of pharmacy professionals released today by Novation, the leading health care services company, found that a move to specialty drug distribution of...

Roche Annual General Meeting 2015

Shareholders approve all proposals by the Board of Directors Richard P. Lifton and Bernard Poussot elected as new Board members 28th consecutive dividend increase Roche (SIX: RO, ROG; OTCQX:...

Amgen Announces Launch Of New Neulasta® (Pegfilgrastim) Delivery Kit

Neulasta Delivery Kit Provides Administration Option for Patients who may not Otherwise Need to Return to Clinic or Hospital the day After Chemotherapy

Mylan Completes Acquisition Of Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business

POTTERS BAR, England and PITTSBURGH, Feb. 27, 2015 /PRNewswire/ -- Mylan N.V. and Mylan Inc. (Nasdaq: MYL) today announced the successful completion of the acquisition of Abbott Laboratories'...

Phase 3 Head-to-Head ENDEAVOR Study Demonstrates Superiority Of Kyprolis® (carfilzomib) Over Velcade® (bortezomib) In Patients With Relapsed Multiple Myeloma

Study Met Primary Endpoint of Progression-Free Survival Patients Receiving Kyprolis Lived Twice as Long Without Disease Progression THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., March...